Curative Biotechnology Inc (CUBT)

[Wrangler1]

From the last press release announcing Dr. Catherine Sohn as an advisor to the Board of Director’s and the CEO:

Paul Michaels, Chairman and President of Curative Biotech stated “We are obviously extremely pleased to have Dr. Sohn on board to oversee our infectious disease programs and our macular degeneration program. Dr. Sohn will also act as the Chairman for the joint steering committees for all three clinical programs. Her impressive background and experience at the highest levels of our industry speaks for itself, and her long involvement in developing novel vaccines will prove invaluable as we develop our next generation Covid-19 vaccine to treat kidney failure patients.”

Sounds like she is pretty engaged to me. Unless of course one can provide evidence to the contrary I will take the Chairman’s input at face value on her level of engagement here. The COVID solution is an extension to IMT504’s use and treatment of rabies. So it is more of an add on to its current application. Smart move imo, particularly since Dr. Sohn started SmithKline Beecham’s vaccine program, including her work there on novel vaccines which is exactly what this would be.

One final note: Dr. Sohn, after a very successful career has her own company now. Her main purpose in life seems to be in helping other company’s and executives succeed. She shares her vast knowledge and experience with others. That is exactly what I do now in consulting in the aviation industry. I have no interest in going to work for a company. So having her as an Advisor seems more prudent than having her as an employee. It would not fit their model nor their cost structure at this time as they are still a developmental stage biotechnology company.